These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16722662)

  • 1. Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior.
    Del Gatto A; Zaccaro L; Grieco P; Novellino E; Zannetti A; Del Vecchio S; Iommelli F; Salvatore M; Pedone C; Saviano M
    J Med Chem; 2006 Jun; 49(11):3416-20. PubMed ID: 16722662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist.
    Belvisi L; Riccioni T; Marcellini M; Vesci L; Chiarucci I; Efrati D; Potenza D; Scolastico C; Manzoni L; Lombardo K; Stasi MA; Orlandi A; Ciucci A; Nico B; Ribatti D; Giannini G; Presta M; Carminati P; Pisano C
    Mol Cancer Ther; 2005 Nov; 4(11):1670-80. PubMed ID: 16275988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
    Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
    Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Combined NMR and Computational Approach to Determine the RGDechi-hCit-αv β3 Integrin Recognition Mode in Isolated Cell Membranes.
    Farina B; de Paola I; Russo L; Capasso D; Liguoro A; Gatto AD; Saviano M; Pedone PV; Di Gaetano S; Malgieri G; Zaccaro L; Fattorusso R
    Chemistry; 2016 Jan; 22(2):681-93. PubMed ID: 26548575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting integrins: insights into structure and activity of cyclic RGD pentapeptide mimics containing azabicycloalkane amino acids.
    Belvisi L; Bernardi A; Colombo M; Manzoni L; Potenza D; Scolastico C; Giannini G; Marcellini M; Riccioni T; Castorina M; LoGiudice P; Pisano C
    Bioorg Med Chem; 2006 Jan; 14(1):169-80. PubMed ID: 16214345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells.
    Maubant S; Saint-Dizier D; Boutillon M; Perron-Sierra F; Casara PJ; Hickman JA; Tucker GC; Van Obberghen-Schilling E
    Blood; 2006 Nov; 108(9):3035-44. PubMed ID: 16835373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probing for integrin alpha v beta3 binding of RGD peptides using fluorescence polarization.
    Wang W; Wu Q; Pasuelo M; McMurray JS; Li C
    Bioconjug Chem; 2005; 16(3):729-34. PubMed ID: 15898744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 2: synthesis of potent alpha(v)beta3/alpha(IIb)beta3 dual antagonists.
    Ishikawa M; Kubota D; Yamamoto M; Kuroda C; Iguchi M; Koyanagi A; Murakami S; Ajito K
    Bioorg Med Chem; 2006 Apr; 14(7):2109-30. PubMed ID: 16309912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bifunctional ligands that target cells displaying the alpha v beta3 integrin.
    Owen RM; Carlson CB; Xu J; Mowery P; Fasella E; Kiessling LL
    Chembiochem; 2007 Jan; 8(1):68-82. PubMed ID: 17154219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part III: synthesis of potent antagonists with alpha(v)beta3/alpha(IIb)beta3 dual activity and improved water solubility.
    Ishikawa M; Hiraiwa Y; Kubota D; Tsushima M; Watanabe T; Murakami S; Ouchi S; Ajito K
    Bioorg Med Chem; 2006 Apr; 14(7):2131-50. PubMed ID: 16307881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New potent and selective αvβ
    Wu Z; Cheng X; Hong H; Zhao X; Zhou Z
    Bioorg Med Chem Lett; 2017 May; 27(9):1911-1913. PubMed ID: 28351594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins.
    Sung V; Stubbs JT; Fisher L; Aaron AD; Thompson EW
    J Cell Physiol; 1998 Sep; 176(3):482-94. PubMed ID: 9699501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of alpha(v)beta3 integrin-like receptor and glycosaminoglycans in Candida albicans germ tube adhesion to vitronectin and to a human endothelial cell line.
    Santoni G; Spreghini E; Lucciarini R; Amantini C; Piccoli M
    Microb Pathog; 2001 Oct; 31(4):159-72. PubMed ID: 11562169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.
    Wilkinson-Berka JL; Jones D; Taylor G; Jaworski K; Kelly DJ; Ludbrook SB; Willette RN; Kumar S; Gilbert RE
    Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1600-5. PubMed ID: 16565398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 1: design and synthesis of a lead compound exhibiting alpha(v)beta3/alpha(IIb)beta3 dual antagonistic activity.
    Kubota D; Ishikawa M; Yamamoto M; Murakami S; Hachisu M; Katano K; Ajito K
    Bioorg Med Chem; 2006 Apr; 14(7):2089-108. PubMed ID: 16309911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.
    Haubner R; Wester HJ; Burkhart F; Senekowitsch-Schmidtke R; Weber W; Goodman SL; Kessler H; Schwaiger M
    J Nucl Med; 2001 Feb; 42(2):326-36. PubMed ID: 11216533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-cytotoxic cobra cardiotoxin A5 binds to alpha(v)beta3 integrin and inhibits bone resorption. Identification of cardiotoxins as non-RGD integrin-binding proteins of the Ly-6 family.
    Wu PL; Lee SC; Chuang CC; Mori S; Akakura N; Wu WG; Takada Y
    J Biol Chem; 2006 Mar; 281(12):7937-45. PubMed ID: 16407244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists.
    Boys ML; Schretzman LA; Chandrakumar NS; Tollefson MB; Mohler SB; Downs VL; Penning TD; Russell MA; Wendt JA; Chen BB; Stenmark HG; Wu H; Spangler DP; Clare M; Desai BN; Khanna IK; Nguyen MN; Duffin T; Engleman VW; Finn MB; Freeman SK; Hanneke ML; Keene JL; Klover JA; Nickols GA; Nickols MA; Steininger CN; Westlin M; Westlin W; Yu YX; Wang Y; Dalton CR; Norring SA
    Bioorg Med Chem Lett; 2006 Feb; 16(4):839-44. PubMed ID: 16298127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical characterization of the binding of echistatin to integrin alphavbeta3 receptor.
    Kumar CC; Nie H; Rogers CP; Malkowski M; Maxwell E; Catino JJ; Armstrong L
    J Pharmacol Exp Ther; 1997 Nov; 283(2):843-53. PubMed ID: 9353406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues.
    Zanardi F; Burreddu P; Rassu G; Auzzas L; Battistini L; Curti C; Sartori A; Nicastro G; Menchi G; Cini N; Bottoncetti A; Raspanti S; Casiraghi G
    J Med Chem; 2008 Mar; 51(6):1771-82. PubMed ID: 18303826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.